The world's second imitation pharmaceutical company split, Novartis plans to cut 1,400 people, half is management

The world's major affairs, the long -term division of the Dishando, Novarta, has made new progress.

On August 25, Novartis global officials announced that they planned to split the imitation drugs and biological pharmaceuticals into a new independent listed company.

Novartis said that the headquarters of Sands after independence is located in Switzerland. This spin -off is expected to be completed in the second half of 2023, and the Demolition of Sands is the largest generic pharmaceutical company in Europe.

Yastez not only has a variety of antibiotics, respiratory, tumors, central nervous nerves and other fields, but also includes 8 biological drugs such as Ada Mutabin, Lifenab, and Yingflisi Mipida. There are 15 biotechnology pipeline products.

The other side of the coin is: As the "patent cliff" expires, the competition in the global pharmaceutical industry is becoming more and more fierce, and the operating income of Sands has continued to decline, and it has dragged down the goal of Nuohua to achieve rapid development.

After more than 3 years of pain and struggle, Novartis Global CEO Wan Sihan finally decided to spill Yamashi. He believes that the two companies of Novartis and Sands have given priority to the distribution of resources, increasing the attention of management for their own business needs, and creating the greatest value for shareholders.

The news of "layoffs and reorganizations" continues

This spin -off has been clues.

In March 2019, as the company's business revenue continued to decline, Richard Francis, who was in charge of five years, resigned. In his resignation statement, he said that Sam Dushi is experiencing the most difficult transformation, and the results of the future cannot be promised, so he is now the best time to leave.

In 2021, the sales of Shanders's generic drug business were US $ 7.5 billion, second only to Israeli Terri, ranking second in global generic drug companies. However, due to multiple factors such as global competitiveness and impact of epidemic conditions, the sales of Sands's generic drug business decreased year by year. In 2020, Sands' sales were $ 7.7 billion.

In September 2018, Novartis once sold Yam Dels' skin diseases and oral solid -system agents in the United States, and sold it to Alabino (US) Pharmaceutical Company at a price of $ 1 billion. Essence However, it was contrary to his wishes. The transaction was rejected by the regulatory authorities and eventually did not take shape.

The fundamental dilemma of Sanders product marketing is that there are no heavy drugs in their hands. In 2019, Novartis Global CEO Wan Sihan implemented a series of major reforms to transform the overall business of Sands.

However, the outside world always believes that Sands will not be able to escape the fate of being sold by Novartis, and news such as "layoffs and reorganizations" has been constantly.

In April 2022, Novartis announced the adjustment of the company's global business framework. It plans to lay off 8,000 people, of which 1,400 are managed by managing positions. At the same time, the two major business departments of pharmaceuticals and tumors are merged into a department. Chinese president and managing director.

Subsequently, the Novartis Chinese team ushered in a number of personnel adjustments. Retail, emerging markets and commerce department, business excellence and operation department, value access department, medical affairs department, strategy and new product planning department all had different degrees of post changes.

However, at that time, the future of the imitation pharmaceutical department, Yam Dex, was still unclear, and even the outside world did not get any news.

On August 24th, Yu Huiming, president of Sam Deza Greater China, announced his departure. The last working day was September 28. He was leaving an announcement that leaving Sands was a very difficult personal decision. At that time, the industry believed that Yu Huiming's departure meant that the overall stripping of Samstes kicked off.

Growth performance is weak

The fate of Sands and Novartis dates back to the 19th century.

In 1886, the chemist Alfred Cohen and businessman Edvat Constant Shanders jointly established a dye factory called Cohen & Shanders Chemical Factory. The two chemical dye factories in Basel and Jiaji in Basel, Switzerland were established.

For many years, the steamba and Sands have shifted to the pharmaceutical industry, while Jiaji mainly produced agricultural chemical business. In 1970, the steamba and Jiaji merged; in 1996, the Steam -Kaji merged with Sam Dushi to become Novartis, and from Shan Dezi Wei Sile became Novarton's first CEO. In 2007, Sands had about 23,000 employees in 130 countries.

In the age of generic drugs, Shanders was smooth and peaceful. However, after the arrival of patented cliffs, the price of generic drugs fell rapidly, and Sands faced fierce competition. According to Novartis's financial report, in 2021, Sands' core operating profit margin decreased from 24.2%of the previous year to 21.4%.

In business rules, if "no more profits are obtained", it is destined to be abandoned.

In the United States, the unit price of Sanders' products has decreased sharply, leading to a significant decrease in final sales and profits. In China in the world's second largest market, Sands is facing the pressure of collecting mining, and the four products have won the bid.

On August 22, Novartis said in a media activity held in Zurich, Switzerland that the company's global structure was adjusted, which not only announced the release of the positions of three company executives, but also planned to be as many as half of the 1,400 jobs of Swiss layoffs. Leading position. This means that in the future, Nohua will have more middle managers to face the fate of being cut.

Obviously, the wave of layoffs in the global biopharmaceutical industry has rolled up. For multinational giants, perhaps the strategic layout of acquisition of mergers and acquisitions and expanding its own physical quantity has been split and replaced by non -core sectors and focusing on core business.

Writing ｜ Editor Lei Gong ｜ Jiang Yun Jia Ting

Operation | Valley

Illustration | Visual China

#Nuohua ## ###

- END -